Pharma Sector

Senores Pharma IPO sees 13.88 times subscription on day two of bidding

Senores Pharmaceuticals' initial public offering garnered 13.88 times subscription on Monday, the day two of bidding. The Rs 582-crore initial share sale got bids for 11,84,54,740 shares, as against 85,34,681 shares on offer, as per NSE data. The portion for Retail Individual Investors (RIIs) received 38.34 times subscription, while the non-institutional investors segment got subscribed 24.48 times. Qualified Institutional Buyers (QIBs) part received 35 per cent subscription. Senores Pharmaceuticals Ltd on Thursday said it has secured nearly Rs 261 crore from anchor investors. The IPO will conclude on December 24. The IPO has a price range of Rs 372-391 per share. The Ahmedabad-based company's IPO is a combination of fresh issuance of shares worth Rs 500 crore and an Offer-for-Sale (OFS) of up to 21 lakh shares valued Rs 82.11 crore, by promoters and other selling shareholders, at the upper-end of the price band. Proceeds from the fresh issue will be utilised for setting up a ...

Here's why Aurobindo Pharma gained 2% in trade on December 23; details here

Aurobindo Pharma share rose after it announced that CuraTeQ Biologics s.r.o., a step-down subsidiary of company, has obtained marketing authorisation from UK's MHRA for Bevqolva

Healthcare, pharma sectors raise Rs 14,811 crore via IPOs in 2024

Record fundraising surpasses the previous high of Rs 9,370 cr in 2023

Here's why Alembic Pharma was buzzing in trade on December 20, details here

Alembic Pharma share rose after the company announced that it has received final approval from the USFDA for its ANDA Divalproex Sodium Delayed-Release Capsules USP, 125 mg

Abbott India share rises 3% as JPMorgan ups target to Rs 31,500; details

The surge in Abbott India share price followed reports that JPMorgan, a New York-based financial services firm, raised its target price to Rs 31,500, up from Rs 30,000, signaling an upside of 12%

Nomura's upgrade to 'Buy' lifts Dr Reddy's share over 4% in weak market

The northward move in Dr Reddy's share price came after Tokyo, Japan-based brokerage Nomura upgraded the stock to 'Buy' from 'Neutral'

Piramal Pharma up 7% as JM Financial initiates with 'Buy'; 36% upside eyed

The uptick in Piramal Pharma share price came after domestic brokerage JM Financial initiated coverage with 'Buy' for a target price of Rs 340

Respiratory drug sales surge as pollution, monsoon drive higher demand

Sales in the respiratory market reached Rs 1,638 crore in November 2024, up from Rs 1,522 crore recorded in October 2024, amid a surge in pollution-related illnesses last month

Metropolis Healthcare to acquire Core Diagnostics for Rs 247 crore

Diagnostic chain Metropolis Healthcare on Monday said it will acquire Core Diagnostics for Rs 247 crore. The company's board has approved the acquisition of 100 per cent stake in Core Diagnostics from its existing shareholder Core Diagnostics (Mauritius) Pvt Ltd, Metropolis Healthcare said in a regulatory filing. Pursuant to the completion of acquisition, Core Diagnostics will become a wholly owned subsidiary of the company, it added. "This strategic acquisition will enhance Metropolis Healthcare's advanced cancer testing capabilities and strengthen its footprint in northern and eastern India," the diagnostic chain said. By leveraging Core Diagnostics' strong relationships with leading cancer specialists and hospitals in these regions, Metropolis aims to expand its market reach and specialised testing offerings, it added. "With approximately 1.4 million new cancer cases and nearly a million deaths annually in India, there is a critical need for advanced cancer testing nationwide.

No shortage of anti-TB drugs in country, two months' stock available: Govt

Centre to launch 100-day campaign in high-TB burden districts on Saturday

Granules India share tanks 10% after USFDA's 'OAI' tag for Gagillapur Unit

The fall in Granules India share price came after the company announced that United States Food and Drug Administration (USFDA) has classified the inspection of Gagillapur unit as OAI

Big Pharma's bet on China biotech a rare trade bright spot amid tensions

Chinese biomedical research is on the cusp of a breakthrough just as the industry starts to face serious headwinds

AstraZeneca Pharma gets nod for sale, distribution of cancer drug Lynparza

The Central Drugs Standard Control Organisation granted approval for the drug's use in combination with Durvalumab for the maintenance treatment of advanced or recurrent endometrial cancer in adults

Orchid Pharma to collaborate with hospital body CAHO to counter AMR

The collaboration aims to tackle AMR in India by focusing on tier 2 and tier 3 cities, bridging the gap between awareness and action, and ensuring sustainable AMR interventions

Why has Aurobindo Pharma stock gained 3% in trade today, November 25?

The collaboration and licencing agreement is set to span three to five years and focuses on the joint development of specific products within the respiratory therapeutic area, Aurobindo Pharma said

Pharma industry expo to be held in Greater Noida from November 26-28

The 17th edition of the CPHI and PMEC expo showcasing the pharmaceutical industry's modernisation, innovation and sustainability will be held from November 26 to 28 in Greater Noida. The expo will this year offer a pivotal marketplace for over 2,000 exhibitors to engage with anticipated participation from countries, including the US, UAE, South Korea, Japan, Egypt, Vietnam, the Philippines, Malaysia, Italy, Sri Lanka, Bangladesh, Nepal, Iran, and the United Kingdom. The expo will showcase over 10,000 products, offering a unique space for collaboration and innovation in the pharma industry, said a release from the organiser Informa Markets in India. The noteworthy exhibitors include Dr Reddy's Laboratories Ltd, Biocon Ltd, Glenmark Lifesciences Ltd, Morepen Laboratories Ltd, Hetero Labs Limited, Lupin Ltd, Signet Excipients Pvt. Ltd, MSN Laboratories Pvt. Ltd, Sekhmet Pharmaventures Pvt. Ltd, Tirupati Lifesciences Pvt. Ltd, Merck Life Science Pvt. Ltd. and many others, the statement

Exports, domestic demand to drive pharma revenue growth: SME Tracker

SMEs manufacture and market formulations based on less complex molecules, given their higher exposure to generic products

Glenmark Pharma Q2 results: PAT rises to Rs 354 cr on chronic drugs demand

The drugmaker reported a consolidated profit of Rs 354 crore (nearly $42 million) for the quarter ended Sept. 30, compared with a loss of Rs 81.95 crore a year ago

India needs to expand local vaccine manufacturing, research: GTRI report

India needs to expand its local vaccine manufacturing and research to give better control over safety of these pharma products, think tank GTRI said on Monday. The Global Trade Research Initiative (GTRI) also suggested the government to launch an investigation to track all adverse health events post-vaccination as this could help make future vaccine rollouts more transparent, safe and effective. "Expanding local vaccine manufacturing and research can give India better control over vaccine safety, ensuring vaccines meet local needs and are tailored to the population's health characteristics," it said in a report. It added that these suggestions assume importance in the backdrop of the October 2024 release of "The Pfizer Papers: Crimes Against Humanity" which has ignited global debate over vaccine safety, ethics and transparency. "As the world prepares for future pandemics, the insights from The Pfizer Papers provide a foundation for building safer, more effective and more trustworth

Indian pharmaceutical market registers over 6% growth in October 2024

The value growth comes at a time when the IPM has registered a negative volume growth of 1.8 per cent